Nikunj Jain was named Chief Financial Officer of Sangamo Therapeutics, Inc, effective February 3, 2026. As of November 14, 2026, Sangamo Therapeutics, Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 3, 2026, naming 1 appointment (Form 8-K, February 3, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Sangamo Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Sangamo Therapeutics, Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-03. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Sangamo Therapeutics, Inc files it.
Layoffs on record: about 51 jobs, latest 2026-06-23 (layoff filings and notices).
Also on the record for Sangamo Therapeutics, Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.38% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Armistice Capital, LLC | 9.75% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G/A, by Wasatch Advisors LP | 2.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Sangamo Therapeutics, Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Sangamo Therapeutics, Inc and the records around it.
Sangamo Therapeutics, Inc elsewhere on the record
Companies that share a holder
- Wasatch Advisors LP also filed stake reports on 72 other companies: Smith Douglas Homes Corp (Oct 2026), Amtech Systems Inc (Oct 2026), BBB Foods Inc (Oct 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Sangamo Therapeutics, Inc
Get an email when Sangamo Therapeutics, Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Sangamo Therapeutics, Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Sangamo Therapeutics, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sangamo Therapeutics, Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-03 | In | Chief Financial Officer | 2026-02-03 | 8-K, 2026-02-03 |
Who leads Sangamo Therapeutics, Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Nikunj Jain, appointed, effective 2026-02-03 (filed 2026-02-03).
New leaders reset buying decisions — get the Full Report on Sangamo Therapeutics, Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Sangamo Therapeutics, Inc, with the record behind each one.
Find candidates like Chief Financial Officer at Sangamo Therapeutics, IncEvery change, in the filing's words
Appointed: Nikunj Jain, Chief Financial Officer, effective 2026-02-03
Effective February 3, 2026, Nikunj Jain, Sangamo's Vice President, Finance and Corporate Controller and principal accounting officer, has been appointed to the position of Interim Chief Financial Officer and will serve as the Company's principal financial officer.
- On February 2, 2026, the employment of Prathyusha Duraibabu, the Company's principal financial officer, terminated.
Tools for this story
Each opens in a new tab, filled in for Sangamo Therapeutics, Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
